1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)-1,8-naphthyridine-3-carboxylic acid | 74274-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)-1,8-naphthyridine-3-carboxylic acid
• 英文别名: 1-ethyl-6-fluoro-4-oxo-7-pyrrolidin-1-yl-1,8-naphthyridine-3-carboxylic acid
• CAS: 74274-63-8
• 化学式: C₁₅H₁₆FN₃O₃
• 分子量: 305.309
• InChiKey: DVGQZGSRNOYAGE-UHFFFAOYSA-N

物化性质

• 沸点：
  530.0±50.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  73.7
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 在 盐酸 、 ammonium hydroxide 、 tetrafluoroboric acid 、 diphenyl ether-biphenyl eutectic 、 magnesium sulfate 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 锌 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 、 氯仿 、 水 、 溶剂黄146 为溶剂， -7.0~249.0 ℃ 、399.97 Pa 条件下， 反应 28.98h， 生成 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  通过balz-schiemann反应合成氟化吡啶。新型抗菌性吡啶酮羧酸依诺沙星的替代途径†

  摘要：

  描述了通过Balz-Schiemann反应对2，6-二取代的3-氨基吡啶5和12的氟化。2,6-二氯-3- pyridinediazonium四氟硼酸盐（6）和2-取代的6-乙酰氨基-3- pyridinediazonium四氟硼酸盐13用或不用溶剂加热，得到相应的氟化吡啶7和14分别，以良好产率。通过已知方法将2-取代的6-乙酰氨基-3-氟吡啶（14）转化为一系列的7-取代的1-乙基-6-氟-1,4-二氢-4-氧代-1,8-萘啶- 3-羧酸21包括新的潜在抗菌剂依诺沙星[1-乙基-6-氟-1,4-二氢-4-氧代-7-（1-哌嗪基）-1,8-萘啶-3-羧酸[（2）] 。

  DOI：

  10.1002/jhet.5570210309

文献信息

• 1,4-Dihydro-4-oxopyridinecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent
  作者：Junichi Matsumoto、Teruyuki Miyamoto、Akira Minamida、Yoshiro Nishimura、Hiroshi Egawa、Haruki Nishimura

  DOI：10.1021/jm00369a011

  日期：1984.3

  or unsubstituted 1-piperazinyl groups were introduced as the C-7 variants. As a result of this study, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine-3-carboxylic acid (named enoxacin, originally AT-2266) was found to show the most broad and potent in vitro antibacterial activity, an excellent in vivo efficacy on systemic infections, and a weak acute toxicity. Structure-activity

  制备具有硝基，氨基，氰基，氯或氟作为C-6取代基的标题化合物。通过6-氨基-1,8-萘啶衍生物9经由其6-重氮盐的Sandmeyer反应，在C-6处引入氯基和氰基。反应扩展到6-氟类似物的合成，涉及四氟硼酸重氮鎓的Balz-Schiemann反应。此外，一系列7-取代的6-氟-1,4-氟-1,4-二氢-4-氧代-1,8的1-乙基，1-乙烯基，1-（2-氟乙基）和1-（二氟甲基）类似物制备了萘啶-3-羧酸。引入1-吡咯烷基，特别是N-取代或未取代的1-哌嗪基作为C-7变体。这项研究的结果是1-乙基-6-氟-1,4-二氢-4-氧代-7-（1-哌嗪基）-1 发现8-萘啶-3-羧酸（命名为依诺沙星，最初为AT-2266）具有最广泛和有效的体外抗菌活性，对全身感染的体内疗效极佳，并且急性毒性也较弱。还讨论了在C-1，C-6和C-7处具有取代基变化的化合物的结构活性关系。
• Naphthyridine derivatives
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04341784A1

  公开（公告）日：1982-07-27

  The present invention provides a 1,8-naphthyridine compound of the formula ##STR1## wherein R is hydrogen, methyl, ethyl or propyl, and a nontoxic pharmaceutically acceptable salt thereof, and a process for preparing a 1,8-naphthyridine compound of the above formula which comprises (A) reacting a compound of the formula ##STR2## wherein Y is halogen, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylsulfonyloxy or arylsulfonyloxy, and R.sub.1 is hydrogen or lower alkyl, with a compound of the formula ##STR3## wherein R.sub.2 is hydrogen or a protective group for the amino group, and R is as defined above, and when a reaction product in which R.sub.1 is lower alkyl and/or R.sub.2 is the amino protective group is obtained, treating it with an acid or base, and/or reductively cleaving it, (B) decomposing a compound of the formula ##STR4## wherein A .crclbar. is a fluorine-containing anion, and R.sub.1 and R.sub.2 are as defined above, and when a reaction product in which R.sub.1 is lower alkyl and/or R.sub.2 is the amino protective group is obtained, treating it with an acid or base, and/or reductively cleaving it, (C) treating a compound of the formula ##STR5## wherein R'.sub.1 is hydrogen or lower alkyl, R'.sub.2 is hydrogen or a protective group for the amino group, provided that R'.sub.1 and R'.sub.2 are not hydrogen atoms at the same time, and R is as defined above, with an acid or base, and/or reductively cleaving it, and optionally converting the resulting compound to a nontoxic pharmaceutically acceptable salt thereof. The 1,8-naphthyridine compound is useful as an antibacterial agent.

  本发明提供了一种1,8-萘啶化合物，其化学式为##STR1##其中R为氢、甲基、乙基或丙基，以及其非毒性药用可接受的盐，并且提供了一种制备上述化合物的1,8-萘啶化合物的方法，包括(A)将化学式为##STR2##其中Y为卤素、较低烷氧基、较低烷基硫基、较低烷基磺酰基、较低烷基磺酰氧基或芳基磺酰氧基的化合物，R.sub.1为氢或较低烷基，与化学式为##STR3##其中R.sub.2为氢或氨基的保护基，R如上所定义，进行反应，当得到R.sub.1为较低烷基和/或R.sub.2为氨基保护基的反应产物时，用酸或碱处理，和/或还原性裂解它，(B)分解化学式为##STR4##其中A .crclbar.为含氟阴离子，R.sub.1和R.sub.2如上所定义，当得到R.sub.1为较低烷基和/或R.sub.2为氨基保护基的反应产物时，用酸或碱处理，和/或还原性裂解它，(C)用酸或碱处理化学式为##STR5##其中R'.sub.1为氢或较低烷基，R'.sub.2为氢或氨基的保护基，前提是R'.sub.1和R'.sub.2不能同时为氢原子，R如上所定义，并可选择将得到的化合物转化为其非毒性药用可接受的盐。1,8-萘啶化合物可用作抗菌剂。
• Naphthyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
  申请人：Société anonyme dite: LABORATOIRE ROGER BELLON

  公开号：EP0027752A1

  公开（公告）日：1981-04-29

  The present invention provides a 1,8-naphthyridine compound of the formula wherein R is hydrogen, methyl, ethyl or propyl, and a nontoxic pharmaceutically acceptable salt thereof, -an antibacterial agent comprising said 1,8-naphtyridine compound -and a process for prearing a 1,8-naphtyridine compound of the above formula which comprises (A) reacting a compound oftheformula: with a compound of the formula or (B) decomposing a compound of the formula or (C) treating a compound of the formula with an acid or base, and/or reducrively cleaving it.

  本发明提供了一种式中 R 为氢、甲基、乙基或丙基的 1，8-萘啶化合物及其无毒的药学上可接受的盐，一种包含上述 1，8-萘啶化合物的抗菌剂，以及一种预制上述式中 1，8-萘啶化合物的工艺，该工艺包括（A）使式中化合物：与式中化合物反应，或（B）分解式中化合物，或（C）用酸或碱处理式中化合物，和/或还原裂解式中化合物。
• MATSUMOTO, JUN-ICHI;MIYAMOTO, TERUYUKI;MINAMIDA, AKIRA;NISHIMURA, YOSHIRO+, J. HETEROCYCL. CHEM., 1984, 21, N 3, 673-679
  作者：MATSUMOTO, JUN-ICHI、MIYAMOTO, TERUYUKI、MINAMIDA, AKIRA、NISHIMURA, YOSHIRO+

  DOI：——

  日期：——
• US4341784A
  申请人：——

  公开号：US4341784A

  公开（公告）日：1982-07-27